Rebecca Suk Heist

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi request reprint A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer
    Rebecca Suk Heist
    Division of Hematology Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    J Thorac Oncol 3:1153-8. 2008
  2. doi request reprint Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer
    Rebecca Suk Heist
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Thorac Oncol 5:1637-43. 2010
  3. pmc FGFR1 amplification in squamous cell carcinoma of the lung
    Rebecca S Heist
    Department or Thoracic Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Thorac Oncol 7:1775-80. 2012
  4. pmc Genetic changes in squamous cell lung cancer: a review
    Rebecca S Heist
    Department of Hematology Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA
    J Thorac Oncol 7:924-33. 2012
  5. pmc EGFR-targeted therapies in lung cancer: predictors of response and toxicity
    Rebecca Suk Heist
    Massachusetts General Hospital Harvard Medical School, Yawkey 7B, 55 Fruit Street, Boston, MA 02114, USA
    Pharmacogenomics 10:59-68. 2009
  6. pmc Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer
    Monica Ter-Minassian
    Department of Environmental Health, Harvard School of Public Health, Boston 02115, MA, USA
    Carcinogenesis 29:2147-52. 2008
  7. doi request reprint VEGF polymorphisms and survival in early-stage non-small-cell lung cancer
    Rebecca Suk Heist
    Massachusetts General Hospital, Harvard School of Public Health, 665 Huntington Ave, Boston, MA 02115, USA
    J Clin Oncol 26:856-62. 2008
  8. pmc Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer
    Rebecca Suk Heist
    Massachusetts General Hospital, USA
    J Clin Oncol 26:5596-602. 2008
  9. ncbi request reprint MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer
    Rebecca Suk Heist
    Massachusetts General Hospital, Boston, MA, USA
    J Clin Oncol 25:2243-7. 2007
  10. ncbi request reprint Matrix metalloproteinase polymorphisms and survival in stage I non-small cell lung cancer
    Rebecca Suk Heist
    Massachusetts General Hospital and Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:5448-53. 2006

Detail Information

Publications12

  1. doi request reprint A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer
    Rebecca Suk Heist
    Division of Hematology Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    J Thorac Oncol 3:1153-8. 2008
    ..We investigated the activity and tolerability of the combination of oxaliplatin, pemetrexed, and bevacizumab in patients with previously treated advanced NSCLC...
  2. doi request reprint Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer
    Rebecca Suk Heist
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Thorac Oncol 5:1637-43. 2010
    ..AT-101 is an oral, pan Bcl-2 family protein inhibitor that has demonstrated activity in small cell lung cancer (SCLC) models. A phase I/II study was conducted combining AT-101 with topotecan in relapsed and refractory SCLC...
  3. pmc FGFR1 amplification in squamous cell carcinoma of the lung
    Rebecca S Heist
    Department or Thoracic Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    J Thorac Oncol 7:1775-80. 2012
    ..Little is known, however, about the clinical and demographic correlates of FGFR1 amplification...
  4. pmc Genetic changes in squamous cell lung cancer: a review
    Rebecca S Heist
    Department of Hematology Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA
    J Thorac Oncol 7:924-33. 2012
    ....
  5. pmc EGFR-targeted therapies in lung cancer: predictors of response and toxicity
    Rebecca Suk Heist
    Massachusetts General Hospital Harvard Medical School, Yawkey 7B, 55 Fruit Street, Boston, MA 02114, USA
    Pharmacogenomics 10:59-68. 2009
    ..This review focuses on the current state of knowledge of predictors of response and toxicity to EGFR inhibitors in lung cancer...
  6. pmc Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer
    Monica Ter-Minassian
    Department of Environmental Health, Harvard School of Public Health, Boston 02115, MA, USA
    Carcinogenesis 29:2147-52. 2008
    ..24, P(gender) = 0.17). No interactions were observed for FAS -1377 G>A and BAT3 Ser625Pro polymorphisms. Our findings indicate that age and smoking may modify the association of the FASLG -844 and IL1B + 3954 SNPs with the risk of NSCLC...
  7. doi request reprint VEGF polymorphisms and survival in early-stage non-small-cell lung cancer
    Rebecca Suk Heist
    Massachusetts General Hospital, Harvard School of Public Health, 665 Huntington Ave, Boston, MA 02115, USA
    J Clin Oncol 26:856-62. 2008
    ..Polymorphisms in the VEGF gene have been identified that are believed to have functional activity. We hypothesized that such polymorphisms may affect survival outcomes among early-stage non-small-cell lung cancer (NSCLC) patients...
  8. pmc Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer
    Rebecca Suk Heist
    Massachusetts General Hospital, USA
    J Clin Oncol 26:5596-602. 2008
    ..We hypothesized that vitamin D levels and VDR polymorphisms may also affect survival among patients with advanced NSCLC...
  9. ncbi request reprint MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer
    Rebecca Suk Heist
    Massachusetts General Hospital, Boston, MA, USA
    J Clin Oncol 25:2243-7. 2007
    ..We hypothesized that the MDM2 G/G genotype may be associated with worse survival outcomes in lung cancer, especially in squamous cell cancers where p53 abnormalities are more common...
  10. ncbi request reprint Matrix metalloproteinase polymorphisms and survival in stage I non-small cell lung cancer
    Rebecca Suk Heist
    Massachusetts General Hospital and Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Clin Cancer Res 12:5448-53. 2006
    ..We hypothesized that polymorphisms in these MMP genes may be associated with survival outcomes in early-stage non-small cell lung cancer (NSCLC)...
  11. ncbi request reprint Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patients
    Wei Zhou
    Department of Environmental Health, Harvard School of Public Health, Boston, MA, USA
    Lung Cancer 53:375-80. 2006
    ..In conclusion, smoking cessation is associated with improved survival in early stage NSCLC patients. The longer the time since cessation of smoking, the better the survival outcome...
  12. ncbi request reprint A phase II study of gefitinib in patients with advanced thyroid cancer
    Nathan A Pennell
    Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Thyroid 18:317-23. 2008
    ..To determine the efficacy of gefitinib in patients with advanced thyroid cancer...